[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Health Network, Toronto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":644},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,253,0,25,[9,52,78,104,134,154,175,197,234,252,278,297,323,353,377,403,424,448,477,500,526,554,581,605,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633240","study-of-high-precision-evaluation-of-molecular-residual-disease-through-a-platform-for-cancer-tracking-and-interception-sherlock-100633240",false,"NCT07524114","Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","SHERLOCK","Inclusion Criteria:\n\n1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.\n2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant\u002Fmaintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.","ALL","18 Years",{"count":20,"type":21},7000,"ESTIMATED","OBSERVATIONAL","This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.",[25,26,27,28,29,30,31,32,33,34],"Breast Cancer","Lung Cancer","Melanoma","Gynecologic Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Tumors",[36,37,38],"Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","RECRUITING","2026-08-19",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-03-31",{"date":47,"type":21},"2031-03-31",{"name":49,"class":50},"University Health Network, Toronto","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100642722","phase-2-capecitabine-in-erher2-negative-breast-cancer-100642722","NCT07631052","Capecitabine in ER+\u002FHER2-negative Breast Cancer","Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER+\u002FHER2-negative Breast Cancer","Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age with histologically confirmed (by local assessment with ASCO\u002FCAP criteria), resected ER-positive\u002FHER2-negative stage I-III breast cancer\n* Evidence of MRD (positive test by the Pathlight assay) despite standard adjuvant therapy\n* No contraindications to capecitabine (including absence of DPYD variants that in the opinion of the investigator are a contraindication to metronomic capecitabine)\n* No clinical or radiographic evidence of recurrent or metastatic disease\n* Previous Therapy requirements: (i) Received at least 24 months of adjuvant endocrine therapy, including 6 months of an aromatase inhibitor and (i) Received at least 12 months of adjuvant CDK4\u002F6i if indicated, unless not tolerated or declined\n* ECOG performance status of 0-1.\n* Patient must have adequate organ function as determined by the following:\n\n  a. Renal function:\n* Serum creatinine \\\u003C 1.5 x ULN (upper limit of normal range) or a calculated creatinine clearance of \\> 50mL\u002Fmin using the Cockcroft-Gault formula\n\n  b. Bone marrow function (without hematopoietic growth factors or transfusion):\n* Absolute neutrophil count (ANC) \\> 1.0 x 109\u002FL\n* Hemoglobin \\> 90 g\u002FL or \\> 9g\u002FdL\n* Platelets \\> 75 x 109\u002FL\n\n  c. Liver function:\n* Total bilirubin ≤ 1.5 × ULN and \\\u003C 35 uMol\u002FL; OR total bilirubin \\>1.5 × ULN with indirect bilirubin \\\u003C 1.5 × ULN.\n* Aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) \\\u003C 2.5 x ULN.\n* Female participants of childbearing potential must have a negative serum β-HCG test result at enrolment.\n* Female participants of childbearing potential must agree to use methods of contraception that are highly effective.\n* Male participants must agree to use methods of contraception that are highly effective.\n* The participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* Signed written and voluntary informed consent.\n\nExclusion Criteria:\n\n* Prior therapy with capecitabine.\n* Previous or concurrent malignancy within 3 years of study entry, with the following exceptions: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other non-invasive or indolent malignancy; other solid tumors treated curatively without evidence of recurrence for at least 3 years prior to study entry.\n* Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\n\n  1. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) \\\u003C6 months prior to screening,\n  2. Symptomatic chronic heart failure (e.g., New York Heart Association Class ≥ 2), history or current evidence of clinically significant cardiac arrhythmia and\u002For conduction abnormality \\\u003C6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia.\n  3. Uncontrolled hypertension defined as persistent elevation of systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100mmHg, despite current therapy.\n* Known positive serology for HIV (Human immunodeficiency virus) that is not currently controlled with antiretroviral therapy.\n* Has a known history of or is positive for active hepatitis B or hepatitis C unless adequate viral suppression is achieved. Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at Screening Visit.\n* Impaired gastrointestinal function or disease that may significantly alter the absorption of capecitabine.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol, or complete the study.",{"count":60,"type":21},15,"INTERVENTIONAL",[63],"PHASE2","This is a Phase 2 study for patients with resected Stage I-III HR+\u002FHER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo\u002Fadjuvant and locoregional therapy delivered with curative intent. In this study participants will be treated with capecitabine. Capecitabine will be administered orally at a dose of 500 mg 3 times daily for up to 12 months, or until the time of clinical recurrence, discontinuation due to toxicity, or withdrawal of consent. This study will have two stages, stage 1 would enroll up to 8 participants to clear the Minimal Residual Disease (MRD) and Stage 2 will enroll up to 5 participants. The purpose of this study is to determine if this study population would have a better outcome from receiving capecitabine rather than having no change in treatment if MRD is detected.",[66,67,68,69],"ER-positive, HER2-negative Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","2026-08-17",{"date":72,"type":43},"2026-08-18",{"date":74,"type":43},"2026-07-29",{"date":76,"type":21},"2029-08-01",{"name":49,"class":50},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":61,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":51},"100652311","functional-electrical-stimulation-plus-high-intensity-interval-training-at-home-100652311","NCT07773974","Functional Electrical Stimulation Plus High Intensity Interval Training at Home","Combining Functional Electrical Stimulation With High Intensity Interval Training at Home","Inclusion Criteria:\n\n1. Be an adult (i.e., ≥18 years old) with a SCI at T12 or above as individuals with a lower motor neuron condition are considered poor candidates for FES.\n2. Have a SCI rated as American Spinal Injury Association Impairment Scale A, B, C or D. If no recent (i.e., in past six months) AIS rating is available in the medical record, the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) exam (Rupp et al. 2021) will be completed by the research team.\n3. Be \\>1 year post-injury, in the case of traumatic SCI, or \\>1 year post-onset of neurological symptoms, in the case of a non-progressive, non-traumatic cause of SCI.\n4. Be able to attend 8 assessment sessions and three education sessions at the Lyndhurst Centre or Rumsey Cardiac Rehab, as well as 36 FES+HIIT@Home sessions and one education session on Microsoft Teams.\n5. Be ambulatory or use a manual wheelchair.\n6. Be able to don\u002Fdoff electrodes independently or with support from a family member or other caregiver.\n7. Have physician clearance to participate in high intensity interval training (i.e., no contraindications to HIIT).\n8. Have an emergency contact who can be reached by the research team during FES+HIIT@Home sessions.\n9. Able to understand spoken English.\n\nExclusion Criteria:\n\n1. Presents with contraindications to FES (i.e. implanted electronic device, radiation in past six months, active deep vein thrombosis, pregnancy) (Houghton et al. 2010).\n2. Presents with cognitive deficits that would prevent independent use of an FES device.\n3. Has irritated and\u002For damaged skin in areas where the electrodes will be applied.\n4. Has a cardiovascular morbidity that would limit exercise tolerance, as identified through pre-intervention cardiorespiratory fitness testing (e.g., complex arrhythmias).\n5. Participant receives a Botox injection or begins a new therapy or exercise program during the first 20 weeks of the study (i.e., prior to the post-intervention assessments).",{"count":86,"type":21},24,[88],"NA","People living with SCI may experience loss of sensation, movement and regular body function. One way to address these impairments is activity-based therapy (ABT), which includes movement-based activities that promote the muscle-brain connection below the level of injury. A technology often used during ABT is functional electrical stimulation (FES), which is an electrical stimulus applied to nerves or paralyzed muscles through sticky gel pads placed on the skin. The purpose of this multi-method pilot study is to look at the safety, interest in and acceptance of an at-home, virtual training program that combines FES with high intensity interval training (HIIT). Up to 24 individuals with SCI will be enrolled in the study. The study activities will span over 34 weeks, from pre-training tests to the 12-week follow-up tests.",[91],"Spinal Cord Injuries (SCI)",[93,94,95],"functional electrical stimulation","high intensity interval training","home-based rehabilitation","NOT_YET_RECRUITING","2026-08-14",{"date":40,"type":43},{"date":100,"type":21},"2026-10-01",{"date":102,"type":21},"2028-07",{"name":49,"class":50},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":61,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":51},"100645543","prt-for-chronic-low-back-pain-100645543","NCT07696741","PRT for Chronic Low Back Pain","Pain Reprocessing Therapy for Chronic Low Back Pain: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Working age adults (18-65)\n* Male or Female at birth\n* Persisting back pain for at least 3 months occurring at least half of the days in the past 6 months\n* Pain score of at least 4\u002F10 (on a 10-point rating scale)\n* Ability to speak and understand English in order to follow study procedures and engage in study interventions.\n\nExclusion Criteria:\n\n* Compensation seeking claim\u002Flitigation\u002FWSIB claim\n* Severe active psychiatric disorders (e.g., psychosis, substance use disorder)\n* An active medical issue such as untreated inflammatory disorder (e.g. ankylosing spondylitis, psoriatic arthritis)\n* Active cancers affecting the spine or body\n* Unexplained unintended weight loss of 20 lbs. or more in the past year\n* Inability to control bowel or bladder, function\n* Individuals who have received or are currently receiving one-on-one or group psychotherapy for chronic low back pain within the past 2 years (e.g., mindfulness, meditation, cognitive behavioural therapy, acceptance and commitment therapy, pain reprocessing therapy, or emotional awareness and exposure therapy).\n* Logistical or technical barriers (e.g. transportation challenges, scheduling constraints, or difficulty using fitness trackers","65 Years",{"count":113,"type":21},30,[88],"The goal of this clinical trial is to learn whether Pain Reprocessing Therapy (PRT) is a feasible and acceptable treatment to complete for working-age adults (ages 18-65) with chronic low back pain. The main questions it aims to answer are:\n\nIs PRT acceptable and feasible for people with chronic low back pain to complete? Does PRT help reduce pain intensity and interference, while improving functional outcomes in people with chronic low back pain?\n\nResearchers will compare PRT to a Monitoring and Education Program to see whether participants who receive PRT experience greater improvements in pain, daily functioning, and well-being.\n\nParticipants will:\n\n* Be randomly assigned to the PRT group or the Monitoring and Education group\n* Participate in 8 intervention sessions over an 8-week period\n* Wear an activity monitor for 8 weeks\n* Attend a follow-up assessment after completing the intervention and another assessment 3 months later\n\nPlease note that ClinicalTrials.gov will be used solely as a public study registry and not as a participant recruitment tool. The study team will not recruit participants or accept self-referrals through ClinicalTrials.gov. All participant recruitment will occur only through the Research Ethics Board (REB) approved recruitment methods.",[117,118],"Chronic Low Back Pain (CLBP)","Nociplastic Pain",[120,121,118,122,123,124,125,126,127],"Chronic Pain","Back Pain","Pain Management","Randomized Controlled Trial","Mind-Body Therapies","Low Back Pain","Rehabilitation","Pilot Projects",{"date":70,"type":43},{"date":130,"type":43},"2026-07-15",{"date":132,"type":21},"2027-06",{"name":49,"class":50},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100550119","extubation-related-complications---the-extube-study-extube-100550119","NCT06442930","EXtubation Related Complications - the EXTUBE Study (EXTUBE)","EXtubation Related Complications - an International Observational Study To Understand the Impact and BEst Practices in the Operating Room and Intensive Care Unit - the EXTUBE Study","EXTUBE","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Undergoing extubation of an endotracheal tube (including index extubation and re-extubations) after general anesthesia in the OR, out of OR anesthesia location or ICU\n* Undergoing extubation during the specified enrollment window\n\nExclusion Criteria:\n\n* Patients will be excluded if the extubation is performed in the context of withdrawal of life support measures,\n* Patients will be excluded if the extubation is performed for tracheostomy decannulation\n\nFor each patient who is not included, reasons for exclusion will be reported.",{"count":143,"type":21},3000,"EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general anesthesia or after critical illness in the operating room (OR), out of OR anesthesia location or intensive care unit (ICU).",[146],"Extubation",{"date":70,"type":43},{"date":149,"type":43},"2025-04-14",{"date":151,"type":21},"2027-12",{"name":49,"class":50},34,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":165,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":174,"locationsCount":51},"100651798","positioning-in-rt---supine-vs-upright-100651798","NCT07765069","Positioning in RT - Supine vs. Upright","Preferences and Perspectives on Supine vs. Upright Positioning in Radiation Therapy","Position in RT","Inclusion Criteria:\n\n1. Pediatric and adult patients aged 3 years and older, undergoing radiation therapy as part of standard clinical care.\n2. Lansky or Karnofsky score 40 or greater\n3. Ability to provide informed consent (or if appropriate, provided by parent or legal guardian).\n4. Ability to understand and speak English or with appropriate assistance","3 Years",{"count":164,"type":21},105,"1 Day","This is a single-center, non-therapeutic prospective pilot cohort study evaluating patient-reported comfort levels between upright and supine positioning in patients receiving radiation therapy across all age groups using a concurrent mixed-methods design.\n\nFollowing standard-of-care RT planning or delivery in the conventional supine position, patients and caregivers will complete a questionnaire evaluating the current treatment position. Patients will then be positioned upright in a chair, using similar immobilization to their supine setup when feasible. This position will be maintained for up to 15 minutes, as tolerated by the patient. During the upright positioning session, patients and caregivers will be asked open-ended questions exploring their perceptions of comfort, stability, and overall experience with the upright chair. No radiation or therapeutic intervention will be delivered during the upright session; the upright positioning procedure is non-therapeutic and conducted solely for assessment purposes. Patients and their caregivers will again be asked to complete a questionnaire evaluating the upright position.\n\nKey stakeholders involved in RT (including Radiation Therapists, Registered Nurses, Radiation Oncologists, or Medical Physicists), will participate in one semi-structured interview to explore perspectives on supine versus upright positioning for RT. Each interview will take up to 60 minutes and will be conducted in-person or virtual using UHN's Microsoft Teams. All sessions will be audio recorded and transcribed on the UHN Microsoft cloud, which is encrypted and stored securely.",[168],"Cancer","2026-08-12",{"date":97,"type":43},{"date":100,"type":21},{"date":173,"type":21},"2027-11-30",{"name":49,"class":50},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":61,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":51},"100578620","phase-2-ctdna-guided-curb-for-opd-mnsclc-on-tki-curb-tki-100578620","NCT06813664","ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)","Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor","CURB-TKI","Inclusion Criteria:\n\n1. Age 18 or older.\n2. Able to do most daily activities (ECOG 0-2).\n3. Able and willing to sign an informed consent form to join the study.\n4. Metastatic disease detected on imaging and histologically confirmed NSCLC on first-line TKI therapy\n5. Willing to give a blood sample for ctDNA analysis.\n6. No upper limit to the number of total metastatic sites, but a maximum of five progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extracranial\n7. Prior radiation therapy near progressive lesions is allowed if applicable.\n8. All sites of oligoprogression that can be safely treated with SBRT or hypofractionated ablative radiotherapy\n9. Oligoprogressive disease is evaluated independently for each lesion using specific criteria.\n10. Stable brain metastases allowed if asymptomatic and do not require corticosteroids.\n11. Oligoprogressive lesions previously treated with external beam radiation are eligible as long they are clinically asymptomatic, and re-treatment is possible according to the investigator. Prior conventional, non-stereotactic radiotherapy for palliative -purposes is allowed, and if the palliated lesion subsequently progressed but remains asymptomatic and does not require immediate radiotherapy, the lesion can still be counted toward one of the five oligoprogressive lesions\n12. Participant is able (i.e. sufficiently fluent or with the assistance of a translator) and willing to complete the quality of life and\u002For health utility questionnaires in English\n13. Accessible for treatment and follow-up.\n\nExclusion Criteria:\n\n1. More than 5 extracranial sites of progressive disease.\n2. Pregnant.\n3. Leptomeningeal disease.\n4. Serious health issues that prevent radiotherapy, like ataxia-telangiectasia or scleroderma.\n5. Prior radiation therapy near the progressive lesion that would prevent treatment with SBRT due to exceeding limits of healthy tissue tolerance.\n6. Any other condition that the investigator believes makes participation in the study inappropriate.",{"count":184,"type":21},60,[63],"This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.",[188,189],"Metastatic NSCLC - Non-Small Cell Lung Cancer","OligoProgressive Metastatic Disease",{"date":191,"type":43},"2026-08-13",{"date":193,"type":21},"2026-09-01",{"date":195,"type":21},"2028-04-01",{"name":49,"class":50},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":204,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":61,"phases":208,"briefSummary":209,"conditions":210,"keywords":218,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":51},"100625026","lifus-for-neurological-disorders-100625026","NCT07417280","LIFUS For Neurological Disorders","Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders","Inclusion Criteria:\n\n* 18-85 years of age\n* Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)\n* Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders\n\nExclusion Criteria:\n\n* History of stroke\n* Comorbid dementia\n* Scored below 22 on the Montreal Cognitive Assessment (MoCA)\n* Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)\n* Presence of metal implanted in body that is contraindicated in TMS\u002FMRI\n* Pregnancy\n* Major depression\u002Fpsychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study\n* Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol\n* Major systemic illness or infection",true,"85 Years",{"count":207,"type":21},50,[88],"Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.",[211,212,213,214,215,216,217],"Parkinson's Disease (PD)","Essential Tremor","Orthostatic Tremor","Dystonia","Epilepsy","Substance Abuse Disorder","Deep Brain Stimulation",[219,212,213,214,215,216,217,220,221,222,223,224,225,226],"Parkinson's Disease","DBS","Substance Use Disorder","SUD","PD","LIFUS","Low-Intensity Focused Ultrasound","Neuromodulation","2026-08-11",{"date":191,"type":43},{"date":230,"type":43},"2025-12-02",{"date":232,"type":21},"2040-12-31",{"name":49,"class":50},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":240,"targetDuration":4,"studyType":61,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":51},"100297566","3t-mri-in-patients-with-deep-brain-stimulation-dbs-100297566","NCT03153670","3T MRI in Patients With Deep Brain Stimulation (DBS)","Inclusion Criteria:\n\n* Age between 18 and 85 years of age\n* Participants must be planned to undergo, or have undergone implantation of DBS electrodes\n* Participants must be able to understand the purpose of this research and must sign the informed consent form.\n* Participants must understand that the role of this research is to enhance our understanding of brain functioning and that he\u002Fshe will not directly or indirectly benefit from the study.\n\nExclusion Criteria:\n\n* Participants who have serious cognitive or psychological impairments and cannot give informed consent.\n* Participants who are unable to effectively or efficiently communicate, for example patients suffering from speech deficits (dysarthria, aphasia) or are non-English speaking.",{"count":241,"type":21},250,[88],"Deep brain stimulation (DBS) is an established treatment for advanced Parkinson's disease, medically refractory tremor, dystonia and obsessive compulsive disorder. Several hypotheses driven DBS trials are underway to study modulation of circuit dysfunction in other neurological and psychiatric disorders like epilepsy, Alzheimer's disease and depression. Recent reports suggest profound effects of DBS on the anatomy and function of downstream areas in the brain. For example electrical stimulation of limbic circuits is associated with increase in hippocampal neurogenesis. Similarly, stimulation of subthalamic nucleus (STN) or globus pallidus (GPi) results in activation of cortical motor circuits. Non-invasive imaging modalities are increasingly being employed in these investigations to better understand the effects of DBS on the structure and function of the brain.\n\nThere have been important advances in MRI and we now have MRI which provides higher resolution and higher quality brain images. More specifically, the investigators propose to use MRI to perform functional magnetic resonance imaging (i.e. fMRI) to assess the effects of deep brain stimulation on brain function and to assess whether fMRI can be used as an adjunct to improve clinical practice in these patients.",[245],"Neuro-Degenerative Disease",{"date":191,"type":43},{"date":248,"type":43},"2017-06-01",{"date":250,"type":21},"2030-12-01",{"name":49,"class":50},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":61,"phases":262,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":51},"100564813","phase-2-pneumonitis-prevention-protocol-using-pentoxifylline-and--tocopherol-in-stage-iii-non-small-cell-lung-cancer-patients-undergoing-chemoradiation-100564813","NCT06634056","Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","P4-PACIFIC","Inclusion Criteria:\n\n* Female and\u002For male aged ≥ 18 years.\n* Histologically confirmed diagnosis of stage III NSCLC, planned for treatment with concurrent chemoradiation and consolidation immune checkpoint inhibitor as per standard of care with no medical contraindications to therapy.\n* Patients with ECOG performance status 0-2 within 4 weeks of randomization.\n* Adequate liver function (no evidence of Child-Pugh class C disease or cirrhosis) as per blood work done within 30 days of registration.\n* Adequate kidney function (Creatinine clearance \\> 50 mL\u002Fmin) as per blood work done within 30 days of registration.\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational product during the last 6 months prior to registration.\n* Patients who will have surgery as part of curative treatment.\n* Previous radiotherapy to intended treatment volumes in the thorax.\n* Active pregnancy.\n* Life expectancy of less than 12 months.\n* Hypersensitivity to Pentoxifylline or other xanthines such as caffeine, theophylline and theobromine or tocopherol (vitamin E).\n* Participant has a history of acute (within 3 months) myocardial infarction, coronary artery disease, or cardiac arrhythmias.\n* Ongoing hemorrhage or major bleeding risk. Patients on antiplatelets agents and anticoagulants (Aspirin, Clopidogrel, Ticlopidine, Cilostazol, Dipyridamole, Heparin, Dalteparin, Enoxaparin and Warfarin) can be enrolled, but major bleeding events will be captured. Patients on Warfarin will need frequent monitoring of their coagulation time to adjust Warfarin dosage.",{"count":261,"type":21},150,[63],"Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI). RT is a highly effect local treatment. However, high doses of radiation used in curative settings can cause adverse side effects. The most common RT side effect in lung cancer is Radiation Induced Lung Injury (RILI), which can manifest as pneumonitis and\u002For pulmonary fibrosis. Lung injury can negatively impact patients' well-being and quality of life, and may lead to increased mortality. Risk of lung injury is particularly increased when patients are treated with a combination of treatments (i.e., RT, chemotherapy, and ICI). The drug Pentoxifylline (in combination with α-Tocopherol (Vitamin E)) has been shown to prevent\u002Falter the progression of lung injury and there is a growing body of evidence to support the safety and efficacy of phosphodiesterase inhibitors in cancer treatment. The proposed study aims to determine if the addition of Pentoxifylline, given in combination with α-Tocopherol (Vitamin E), to standard of care treatment will reduce side effects related to lung injury and improve quality of life in this study population.",[265,266],"Non-Small Cell Lung Cancer","Radiation Induced Lung Injury (RILI)",[258,266,265,268,269],"Pentoxifylline","α-Tocopherol (Vitamin E)","2026-08-05",{"date":272,"type":43},"2026-08-06",{"date":274,"type":43},"2026-06-15",{"date":276,"type":21},"2032-11-30",{"name":49,"class":50},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":61,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":51},"100522681","a-study-of-head-and-neck-mri-and-tumor-microenvironment-biomarkers-100522681","NCT06085781","A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers","HN-BIO: A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers","HN-BIO","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years\n* Histologically proven Head and Neck Squamous Cell carcinoma\n* Primary or nodal disease \\> 3cm for biomarker imaging\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Planned for curative surgery or (chemo)radiotherapy\n* Willingness to undergo repeat MRI imaging\n* Able to receive and understand verbal and written information regarding study and able to give written informed consent\n* Adequate renal function: Calculated creatinine clearance \\>\u002F= 30ml\u002Fmin\n* Be able to lie comfortably on back for 1 hour\n\nExclusion Criteria:\n\n* As judged by investigator evidence of systemic disease that makes unsuitable for study\n* Contra-indication for serial MRI scans\n* Previous solid tumor treated within last 5 years\n* Pregnancy\n* History of gadolinium contrast allergy\n* Non-reversible clotting abnormality",{"count":184,"type":21},[88],"The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.",[290],"Squamous Cell Carcinoma of Head and Neck",{"date":272,"type":43},{"date":293,"type":43},"2024-01-29",{"date":295,"type":21},"2027-01-15",{"name":49,"class":50},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":51},"100650500","reliability-of-diaphragm-ultrasound-intra--and-interrater-analysis-100650500","NCT07747532","Reliability of Diaphragm Ultrasound: Intra- and Interrater Analysis","ReDU analysis","Inclusion Criteria:\n\nParticipants must meet all the following inclusion criteria to be eligible for the study:\n\n1. Any elective surgical patient\n2. Age ≥18 years\n3. American Society of Anesthesiologists class I to III\n\nExclusion Criteria:\n\nParticipants will not be eligible for the study if any of the exclusion criteria is present:\n\n1. Pregnancy - patients will be asked if they are pregnant or not and screened post-consent from their medical chart.\n2. History of diaphragmatic dysfunction\n3. Previous surgical procedures on the lung, thorax or diaphragm.\n4. Inability to understand the study activities and provide informed consent when explained about the study and the consent process\n5. Refusal to participate in study",{"count":305,"type":21},58,"It is often difficult for anesthesiologists to select an ultrasound method that will give consistent results and also be a reliable way to examine the diaphragm, especially on the left side of the chest.\n\nIn this study, two anesthesiologists blinded to one another's scan results, will perform ultrasound scan of the diaphragm using three different methods and the measurements will be analyzed to see the reliability of each method.",[308],"Diaphragm Issues",[310,311,312,313,314,315,316],"Diaphragm ultrasound","Intra-rater analysis","Inter-rater analysis","Zone of Apposition, ZOA","Diaphragmatic diseases","Dome of diaphragm, DOD","Thickening Fraction, TF","2026-07-30",{"date":270,"type":43},{"date":320,"type":21},"2026-08",{"date":102,"type":21},{"name":49,"class":50},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":331,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":61,"phases":334,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":51},"100650421","68ga-psma-11-petmri-for-selecting-men-with-prostate-cancer-for-focal-therapy-100650421","NCT07747493","68Ga-PSMA-11 PET\u002FMRI for Selecting Men With Prostate Cancer for Focal Therapy","The Role of 68Ga-PSMA-11 PSMA PET\u002FMRI in Selecting Patients With Prostate Cancer for Focal Therapy: A Pilot Study","PSMA-FT","Inclusion Criteria:\n\n* Ability to provide written informed consent.\n* Age 18 years or older.\n* Clinically significant prostate cancer (csPCa) with clinical stage ≤ T2c and planned radical prostatectomy.\n* Serum prostate-specific antigen (PSA) ≤ 20 ng\u002FmL.\n* Clinically significant prostate cancer within an MRI-visible lesion, defined as - International Society of Urological Pathology (ISUP) Grade Group 2 or 3 (Gleason score 3+4 or 4+3) in any biopsy core.\n\nExclusion Criteria:\n\n* Inability to lie still for the PET\u002FMRI examination.\n* Known contraindication or hypersensitivity to gallium Ga 68 gozetotide (68Ga-PSMA-11) or to the MRI gadolinium contrast agent, including any component of the formulation.","MALE",{"count":333,"type":21},8,[88],"Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with the goal of preserving urinary and sexual function. Successful focal therapy depends on accurately identifying all areas of clinically significant prostate cancer before treatment. Currently, multiparametric magnetic resonance imaging (MRI) is the standard imaging method used to determine whether a patient is a suitable candidate for focal therapy. However, MRI may miss some clinically significant cancers, which can lead to incomplete treatment.\n\nThis pilot study will evaluate whether 68Ga-PSMA-11 positron emission tomography\u002Fmagnetic resonance imaging (PET\u002FMRI) can improve the selection of men with localized prostate cancer for focal therapy compared with MRI alone. The study will enroll men with intermediate-risk prostate cancer who are already planning to undergo radical prostatectomy as part of their standard care.\n\nParticipants will receive a single injection of 68Ga-PSMA-11 followed by a PET\u002FMRI scan before surgery. The PET\u002FMRI findings and MRI findings will be reviewed separately and compared with the prostate tissue examined after surgery, which serves as the reference standard for determining the true location and extent of cancer.\n\nThe main question this study is trying to answer is whether 68Ga-PSMA-11 PET\u002FMRI is more accurate than MRI alone in identifying men who are appropriate candidates for focal therapy. The study will also evaluate whether PET\u002FMRI detects more clinically significant prostate cancer lesions than MRI alone.\n\nResearchers hypothesize that 68Ga-PSMA-11 PET\u002FMRI will improve the detection of clinically significant prostate cancer and more accurately identify patients who are suitable candidates for focal therapy, potentially reducing the risk of untreated cancer remaining in the prostate after treatment. If successful, the results of this pilot study will support the development of a larger clinical trial and may help improve future treatment planning for men with localized prostate cancer.",[337,338],"Prostate Cancer (Adenocarcinoma)","Localized Prostate Cancer",[340,341,342,343,344,338,345,346,347],"Prostate Cancer","Gallium Ga 68 Gozetotide","Positron Emission Tomography Magnetic Resonance Imaging","Multiparametric Magnetic Resonance Imaging","Focal Therapy","Intermediate-Risk Prostate Cancer","Radical Prostatectomy","Diagnostic Imaging",{"date":270,"type":43},{"date":193,"type":21},{"date":351,"type":21},"2027-12-31",{"name":49,"class":50},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":61,"phases":363,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":51},"100643024","simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain-100643024","NCT07636382","Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain","A Prospective Pilot Clinical Trial of Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain","Celiac SRS","Inclusion Criteria:\n\n* Subjects must have histologically or cytologically confirmed cancer that is metastatic or unresectable, and considered appropriate per the treating physician to receive celiac plexus SBRT.\n* Age \\>18 years. Because no data are currently available on the use of celiac axis SBRT in subjects ≤18 years of age, children are excluded from this study.\n* Performance status: ECOG Performance status ≤ 3\n* Severe retroperitoneal pain syndrome (radiates from the lower back to the upper abdomen, belt- like distribution), intensity of at least 5 on 11-point Brief Pain Inventory (BPI, average pain) scale.\n* Subjects must have anatomical involvement of the celiac plexus on the diagnostic CT, PET\u002FCT, or MRI. This includes: Any pancreatic cancer, any other cancer that on imaging demonstrates either gross involvement of the celiac blood vessels or celiac plexus on imaging OR haziness around the celiac blood vessels that typically implies tumor engulfment.\n* Prior chemotherapy or biological treatment is allowed, but any active oncological treatment should be stopped at least 1 week prior to radiation therapy and renewed at least 1 week following radiation therapy.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n* Subjects must have a diagnostic CT of the abdomen and pelvis, with or without contrast, acquired \\\u003C 28 days prior to the study consent.\n\nExclusion Criteria:\n\n* In ability to tolerate lying supine and still for at least 45 minutes.\n* Performance status: ECOG Performance status of 4.\n* Previous radiotherapy to the upper abdomen overlapping with the projected site of treatment.\n* Pregnant or breastfeeding women are excluded from this study.\n* Subjects with conditions associated with increased risk of side effects from radiation such as inflammatory bowel disease and scleroderma.\n* Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. If pregnancy test is not clinically indicated as determined by treating physician or protocol principal investigator, documentation of this exception is sufficient in lieu of a pregnancy test.",{"count":362,"type":21},5,[88],"This is a prospective, single-arm, pilot feasibility clinical trial designed to evaluate the feasibility and safety of a simulation-free adaptive radiotherapy workflow to enable single-session celiac plexus SBRT planning and delivery. In this trial, the treatment itself is non-investigational (standard-of-care celiac plexus SBRT) but the treatment workflow (simulation-free, using adaptive radiotherapy to compress treatment planning and delivery into a single session) is novel. Investigators hypothesize the successful completion of the simulation-free ART workflow through treatment delivery in the first on-table treatment attempt for at least 80% of patients.",[366,367],"Advanced Cancer","Pancreatic Cancer",[369,370,367],"SBRT","Celiac",{"date":317,"type":43},{"date":373,"type":43},"2026-06-04",{"date":375,"type":21},"2027-06-01",{"name":49,"class":50},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":51},"100642555","shoulder-ra-survey-study-100642555","NCT07641842","Shoulder RA Survey Study","Patient Experience of Benefits and Limitations of Single Injection Peripheral Nerve Block for Shoulder Surgery: A Cross-sectional Survey","RA","Inclusion Criteria:\n\nParticipants must meet all the following inclusion criteria to be eligible for the study:\n\n1. Patients receiving a single-injection PNB for outpatient arthroscopic shoulder surgery at TWH and WCH\n2. Age ≥18 years\n3. Able to communicate in English\n\nExclusion Criteria:\n\n1. Cognitive impairment (inability to consent to participate in study)\n2. Refusal to participate in study\n3. Patients with primary block failure defined as those without a detectable sensory or motor block (determined by inability to abduct the arm and numbness or loss of sensation to pinprick over lateral shoulder\u002Fdeltoid muscle, C5 dermatome)",{"count":386,"type":21},140,"The purpose of this study, called a cross-sectional survey, is to interview patients on their experiences of pain and recovery following keyhole shoulder surgery, after receiving a single shot nerve block in addition to a general anesthetic. The researchers would like to explore patients' experiences to see if there are groups of patients who may benefit from insertion of a nerve catheter as compared to a single shot nerve block injection for keyhole shoulder surgery.",[389],"Nerve Block",[391,392,393,394,395],"Nerve block","Nerve catheter block","Shoulder Arthroscopic Surgery","Survey","Continuous nerve block catheter infusion",{"date":397,"type":43},"2026-07-31",{"date":399,"type":43},"2026-06-05",{"date":401,"type":21},"2026-12-31",{"name":49,"class":50},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":204,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":51},"100639282","ai-for-gastric-pocus--point-of-care-ultrasound-100639282","NCT07580456","AI for Gastric POCUS ( Point-of-care Ultrasound)","Development of an Artificial Intelligence Algorithm to Enhance the Gastric Point-of-care Ultrasound. A Proof-of-concept Study.","POCUS","Inclusion Criteria:\n\nA. Inclusion Criteria at the level of the participants\n\n* Participants must meet all the following inclusion criteria to be eligible for the study:\n\n  * Aged ≥18 years\n  * Any sex\n  * Be healthy\n\nB. Inclusion Criteria at the level of the input data • Transverse ultrasound images (10 sec clips) of the gastric antrum in the epigastric area that contain all these structures:\n\n* The edge of the left lobe of the liver\n* The gastric antrum\n* The pancreas\n* The aorta\n\nExclusion Criteria:\n\nA. Exclusion Criteria at the level of the participants\n\n* Participants meeting any of the following exclusion criteria are ineligible for the study:\n\n  * Previous gastro-esophageal surgery (e.g., gastric by-pass, sleeve gastrectomy, fundoplication, partial gastrectomy)\n  * Allergy to any of the food that will be provided.\n\nB. Exclusion Criteria at the level of the input data\n\n• Ultrasound images (10 sec clips) where the gastric antrum cannot be positively identified.",{"count":113,"type":21},"The goal of this observational study is to train and test an AI (Artificial Intelligence)-based program to assist anesthesiologists in the interpretation of stomach ultrasound images and differentiate a \"full\" from an \"empty\" stomach.\n\nIt is a healthy-volunteer study, where the participants will undergo ultrasound examination of their stomach at three different time points to visualize the stomach contents. These are at fasting state, after taking some solid food and after taking some water. Here, the participants will be randomized to receive one of five different types solid foods and one of five different volumes of water. The stomach ultrasound images will then be used to train and test the accuracy of the model to diagnose the type of stomach content (nothing vs. clear fluid vs. solid food)",[414],"Point-of-care Ultrasound",[416,417,418],"Artificial Intelligence","POCUS (Point-of-care ultrasound)","Ultrasound",{"date":397,"type":43},{"date":421,"type":43},"2026-05-05",{"date":351,"type":21},{"name":49,"class":50},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":331,"minAge":18,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":61,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":447},"100470307","phase-2-duration-of-androgen-receptor-pathway-inhibitor-and-adt-with-metastasis-directed-therapy-in-oligometastatic-cancer-of-the-prostate-direct-100470307","NCT05404139","Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)","Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate","DIRECT","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Able to provide informed consent\n3. Histologic diagnosis of prostate adenocarcinoma\n4. ECOG performance status 0-2\n5. Stage IV castrate sensitive metachronous metastatic prostate cancer. diagnosed within 6 months of study enrollment with 1-10 metastases\n\n   1. Maximum one metastatic deposit on conventional imaging (CT or bone scan or MR)\n   2. Additional metastases can be detectable by PSMA PET only\n6. All sites of disease are amenable to and can be safely treated with radiotherapy\n7. Patients decline continuous use of ADT\n\nExclusion Criteria (for all patients):\n\n1. Significant comorbidities rendering patient not suitable for ADT, ARPI (enzalutamide or abiraterone) and SBRT\n\n   a. Patients with significant comorbidities rendering patient not suitable for atorvastatin is not an exclusion criteria, as these patients can still enroll and be randomized between Arms 1 and 3.\n2. History of malignancy within the past 5 years, excluding non-melanoma skin cancer and in-situ cancer, managed non-curatively\n3. Prior use of salvage systemic therapy\n4. Evidence of spinal cord compression\n\nExclusion Criteria (for Arm 4 only, after randomization)\n\n1. ALT\u002FAST \\> 3 x ULN\n2. History of myasthenia gravis or active myasthenia gravis\n3. History of ocular myasthenia or active ocular myasthenia","100 Years",{"count":434,"type":21},352,[63],"This is a multi-centre, investigator-initiated, three-arm, randomized trial to investigate the addition on androgen receptor pathway inhibitor and atorvastatin to standard of care radiation and hormone therapy improve quality of life.\n\nParticipants will either receive standard of care radiation and hormone (ADT) therapy (Arm 1), standard of care radiation and hormone (ADT) therapy plus oral abiraterone for 8-9 months (Arm 3) or standard of care radiation and hormone (ADT) therapy plus oral abiraterone for 8-9 months plus atorvastatin for 2 years (Arm 4). Participants will be routinely follow-up in clinic or remotely for up to 5 years.",[438],"Metastatic Prostate Cancer","2026-07-23",{"date":441,"type":43},"2026-07-27",{"date":443,"type":43},"2023-05-24",{"date":445,"type":21},"2031-02",{"name":49,"class":50},2,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":456,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":61,"phases":459,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":51},"100471936","phase-4-intravenous-vs-oral-acetaminophen-in-postoperative-hip-fracture-adult-patients-100471936","NCT05425355","Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult Patients","INTACT-HIP: INTravenous Acetaminophen vs. Oral Randomized Controlled Trial in HIP Fracture Patients - a Feasibility Trial","INTACT-HIP","Inclusion Criteria:\n\n* 60 years of age and older\n* Patients who were ambulating without human assistance before fracture, with any type of non-neoplastic hip fracture\n* Patients undergoing surgical treatment as an inpatient\n\nExclusion Criteria:\n\n* Patients with neoplastic hip fracture\n* Severe cognitive impairment (Montreal Cognitive Assessment (MoCA) \\\u003C10)\n* Pre-existing delirium\n* Known hypersensitivity or allergy to acetaminophen\n* Severe or chronic liver or kidney dysfunction\n* Planned postoperative ventilation\n* Swallowing issues and\u002For dysphagia\n* English language limitation\n* Weight \\\u003C50kg","60 Years",{"count":458,"type":21},42,[460],"PHASE4","The INTACT-HIP trial study will evaluate feasibility of conducting a randomized, double-blinded controlled trial comparing postoperative treatment with intravenous (IV) acetaminophen versus oral acetaminophen, in older adults undergoing hip fracture surgery.\n\nThe results of this feasibility trial will be used to inform designing a larger, multi-center, randomized controlled trial to assess the efficacy of IV acetaminophen compared to oral acetaminophen to reduce delirium and improve other clinical and patient-centered outcomes after hip fracture surgery. It will randomize 42 older adults to receive either oral or IV acetaminophen after hip fracture surgery.",[463,464],"Hip-fracture","Surgery",[466,467,468,469],"elderly","acetaminophen","oral vs intravenous","hip fracture surgery","2026-07-22",{"date":439,"type":43},{"date":473,"type":43},"2023-01-23",{"date":475,"type":21},"2026-12-30",{"name":49,"class":50},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":485,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":51},"100402884","real-world-evidence-in-patient-reported-outcomes-for-medical-cannabis-mc-rwe-100402884","NCT04526093","Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)","MC-RWE : Real World Evidence in Patient-Reported Outcomes for Medical Cannabis: A Prospective Observational Study","MC-RWE","Inclusion Criteria:\n\n* Subjects (≥19 years of age) who are MC-naïve or -experienced with a medical authorization for MC provided by a prescribing health care practitioner and who have provided informed consent\n* Primary therapeutic indications for MC use: pain, epilepsy, sleep, and\u002For anxiety\u002Fdepression.\n* Subjects agree to use verified products and refrain from using any other cannabis products, either medical or recreational, during the duration of the study\n\nExclusion Criteria:\n\n* Concomitant use of illicit drugs\n* Concomitant use of recreational cannabis","19 Years",{"count":487,"type":21},1000,"This prospective observational study aims to describe the effectiveness of MC on pain, epilepsy, sleep and \u002For anxiety\u002Fdepression in a cohorts of patients authorized to use MC, using pre-defined, validated self assessment scales.",[490,491,492,493,215],"Pain","Sleep","Anxiety","Depression","2026-07-20",{"date":470,"type":43},{"date":497,"type":43},"2020-07-15",{"date":102,"type":21},{"name":49,"class":50},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":508,"minAge":18,"maxAge":509,"enrollmentInfo":510,"targetDuration":4,"studyType":61,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":525},"100484813","partial-breast-re-irradiation-using-ultra-hypofractionation-preserve-100484813","NCT05592938","Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)","Partial Breast Re-irradiation Using Ultra Hypofractionation: Phase 2 Multi-institutional Study (PRESERVE)","PRESERVE","Inclusion Criteria:\n\n* Age \\> 18 years\n* In-breast recurrence or new primary (ductal carcinoma in situ (DCIS) or invasive carcinoma)\n* Tumour \\\u003C3.0 cm in greatest diameter on pathologic examination, including both invasive and non-invasive components\n* \\>5 years after completion of prior adjuvant whole or partial breast radiotherapy (prior nodal radiotherapy permitted)\n* Clinically node negative\n* Negative margins (no tumour on ink)\n* Recovered from surgery with the incision completely healed and no signs of infection\n\nExclusion Criteria:\n\n* Multicentric disease (patients with multifocal breast cancer in the same quadrant are eligible)\n* Tumour histology limited to lobular carcinoma only\n* T4 disease\n* Node positive or distant metastatic disease\n* Serious non-malignant disease (cardiovascular, pulmonary, systemic lupus erythematosus, scleroderma), which would preclude radiation treatment\n* Currently pregnant or lactating\n* Presence of an ipsilateral breast implant or pacemaker\n* Unable to commence radiation within 16 weeks of breast-conserving surgery (or last surgical procedure on the breast) or within 12 weeks from last cycle of adjuvant chemotherapy\n* Unable to clearly define the surgical cavity (oncoplastic procedures are permitted provided the tumor bed is well delineated with surgical clips).\n* Psychiatric disorders which would preclude obtaining informed consent or adherence to protocol\n* Grade II or more late skin toxicity from prior radiation evaluated and graded using CTCAE v5.0\n* Current or prior diagnosis of bilateral breast cancer","FEMALE","99 Years",{"count":511,"type":21},171,[88],"Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalent to longer fractionation schedules in the upfront treatment setting. These 1-week schedules are more convenient for patients, with fewer treatments and shorter overall treatment time. The investigators hypothesize that a 1-week ultra-hypofractionated rPBI regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR) will be associated with acceptable toxicity at 1 year (\\\u003C13% grade \\>3 toxicity).",[25,515],"Breast Cancer Recurrent",[517],"Hypofractionated",{"date":519,"type":43},"2026-07-17",{"date":521,"type":43},"2023-06-27",{"date":523,"type":21},"2027-06-27",{"name":49,"class":50},19,{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":534,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":61,"phases":538,"briefSummary":539,"conditions":540,"keywords":543,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":553},"100583599","cannabinoids-for-osteoarthritis-pain-effectiveness-trial-100583599","NCT06878417","Cannabinoids for Osteoarthritis Pain Effectiveness Trial","The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: an Internal Pilot, Placebo Controlled, Blinded Randomized Trial","COPE","Inclusion Criteria:\n\n1. Age 40-80 years\n2. Diagnosed with hip and\u002For knee osteoarthritis as per the American College of Rheumatology criteria\n3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60\n4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks\n5. Able to self-report, understand and read English or French\n\nExclusion Criteria:\n\n1. Hip or knee surgery planned in the coming 4 months,\n2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.),\n3. Planned injection into the affected joint(s) during trial period,\n4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.),\n5. Contraindications to taking cannabis\u002Fcannabinoids,\n6. Used nabilone or nabiximols in the last 30 days,\n7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout),\n8. A history of diagnosed cannabis use disorder or dependence,\n9. Active substance use disorder,\n10. Current DSM-V diagnosis of bipolar disorder, major depression, or psychosis,\n11. An uncontrolled medical or major psychiatric disorder,\n12. Currently on warfarin,\n13. Known pregnancy or currently breastfeeding,\n14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs\n15. No fixed address or a plan to change addresses in the coming 4 months,\n16. Known or suspected allergy to palm\u002Fcoconut oil","40 Years","80 Years",{"count":537,"type":21},100,[88],"This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy.\n\nThe goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and\u002For knee osteoarthritis.\n\nParticipants will:\n\n* Take either CBD, THC, or a placebo capsule daily for 8 weeks\n* Complete follow-ups remotely, with no in-person clinic visits required\n* Maintain a diary tracking their study drug usage and any additional pain medications",[541,542],"Osteoarthritis of Knee","Osteoarthritis Hip",[544],"Medical Cannabis","2026-07-14",{"date":547,"type":43},"2026-07-16",{"date":549,"type":43},"2026-01-29",{"date":551,"type":21},"2027-02-28",{"name":49,"class":50},3,{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":61,"phases":563,"briefSummary":564,"conditions":565,"keywords":569,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":51},"100645899","well-being-program-for-caregivers-of-patients-with-advanced-cardiac-and-pulmonary-disease-100645899","NCT07685912","Well-being Program for Caregivers of Patients With Advanced Cardiac and Pulmonary Disease","Enhancing Caregiver Wellbeing: The Role of Exercise, Nutrition, and Stress Management for Caregivers of Patients With Advanced Cardiac and Pulmonary Disease","INCLUSION CRITERIA (CAREGIVERS):\n\n* Informal (unpaid) caregivers aged 18 years or older\n* Identified as the primary caregiver of a patient with advanced cardiac or pulmonary disease receiving outpatient palliative care at Toronto General Hospital\n* Ability to provide informed consent\n\nEXCLUSION CRITERIA (CAREGIVERS):\n\n* Presence of any medical condition where moderate physical activity or exercise training would be contraindicated (e.g., unstable cardiovascular disease, recent injury)\n* Significant cognitive impairment or language barrier that would interfere with completing study procedures\n* Lack of access to a phone or internet connection to enable virtual participation\n\nINCLUSION CRITERIA (Patients):\n\n* Aged 18 years or older\n* Diagnosis of advanced cardiac or pulmonary disease and currently receiving outpatient palliative care at Toronto General Hospital\n* Ability to provide informed consent\n\nEXCLUSION CRITERIA (Patients):\n\n* Significant cognitive impairment or language barrier that would interfere with completing study procedures\n* Medical instability that would preclude participation in an interview or completion of questionnaires, as determined by the clinical team\n* Lack of access to a phone or internet connection to enable virtual participation",{"count":562,"type":21},80,[88],"Caregivers provide essential support for people living with advanced heart or lung disease, including daily tasks, emotional support, and help with medical care. Although their role is vital, caregivers often experience high levels of stress, fatigue, and challenges with their own health and well-being. This study will test whether it is possible and practical to offer an 8-week wellness program for caregivers that is delivered virtually in their homes. The program includes personalized strategies for physical activity or exercise, healthy eating, and stress management. It will be tailored to the individual needs and schedules of caregivers and supported by regular virtual check-ins with health professionals. We will evaluate whether caregivers find the program acceptable, safe, and feasible to follow. This includes looking at how many caregivers agree to participate, how many complete the program, whether they can follow the activities, and whether they are satisfied with the experience. The study will also explore whether participating in the program may lead to improvements in caregiver quality of life, stress, and confidence in the caregiving role.",[566,567,568],"Caregiver","Cardiac Disease","Pulmonary Diseases",[570,571,572,573],"Exercise","Nutrition","Stress management","Well-being","2026-07-09",{"date":576,"type":43},"2026-07-13",{"date":130,"type":21},{"date":579,"type":21},"2028-03-30",{"name":49,"class":50},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":588,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":61,"phases":590,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":51},"100610692","prospective-reduction-of-transplant-complications-through-enhanced-preservation-therapy-to-prevent-primary-graft-dysfunction-100610692","NCT07230886","Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction","PROTECT-PGD","Inclusion Criteria:\n\n* Recipient: Adult (\\>17 years old)\n* Donor: Donation after brain death acceptable for transplant as determined by a procuring physician unaware of randomization sequence at the time of acceptance\n\nExclusion Criteria:\n\n* Recipient: Multi-organ transplant recipients; Participating in an interventional study.\n* Donor: Donation after cardiac death; Use of organ care system","17 Years",{"count":207,"type":21},[88],"The goal of this clinical trial is to test the feasibility of the study protocol comparing a novel temperature control system - Xo Port Organ Preservation System - to static ice for heat preservation for Heart Transplant. The main questions of the study are as follows:\n\nDoes the Incidence of severe PGD change within the first 24 hours of heart transplant in patients randomized to the Xo Port Organ Preservation System?\n\nWas there a change in composite efficacy endpoints in participants randomized to the Xo Port Organ Preservation System compared to static ice storage?\n\nWere the feasibility outcomes achieved?\n\nWere there any protocol deviations?\n\nParticipants will:\n\nBe randomized to either the Xo Port Organ Preservation System or static ice storage.\n\nComplete a questionnaire at the time of screening, day 0, 7, and 90 days post transplant.\n\nHave blood drawn - with their standard of care blood draws - after their transplant, the day after, and 7 days post transplant.",[593],"Primary Graft Dysfunction",[593,595,596,597,598],"Transplant","Traferox","Preservation Therapy","X Port Preservation System",{"date":576,"type":43},{"date":601,"type":43},"2026-04-17",{"date":603,"type":21},"2028-12",{"name":49,"class":50},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":61,"phases":613,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":621,"leadSponsor":623,"locationsCount":4},"100645995","phase-1-enhancing-icb-efficacy-through-il-1-inhibition-in-tnbc-100645995","NCT07698106","Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","Rebooting Sensitivity to Checkpoint Blockade Therapy in Triple-Negative Breast Cancer With Isunakinra (RESETT- I)","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Newly diagnosed, locally advanced, previously untreated and centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines, and staging per current AJCC staging criteria for breast cancer as assessed by the investigator based on radiological and\u002For clinical assessment:\n\n   Clinical stage T1c\u002FN1-N2, T2-4\u002FN0-2\n3. Provides core needle biopsies consisting of at least 2 separate tumor cores from the primary tumor to the central laboratory\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n5. Demonstrates adequate organ function\n6. Participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study\n\nExclusion Criteria:\n\n1. Male Gender\n2. Luminal A\u002FB and HER2 positive breast cancer\n3. Multifocal early breast cancer\n4. History of invasive malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n5. Received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months\n6. Has received prior therapy with an anti-PD1, anti-PDL1\u002F-PDL2 agent or with an agent directed to another co-inhibitory T-cell receptor\n7. Participated in an interventional clinical study with an investigational compound or device within 4 weeks of randomization for this study\n8. Pre-existing inflammatory arthritis\n9. Has received a live vaccine within 30 days of the first dose of study treatment\n10. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)\n11. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (i.e., dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment\n12. Active or uncontrolled Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C\n13. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis\n14. Has an active infection requiring systemic therapy\n15. Has significant cardiovascular disease\n16. Is pregnant or breastfeeding, or expecting to conceive children within the duration of the study\n17. Has a known history of active tuberculosis (TB, Bacillus Tuberculosis)\n18. Platelets ≤ 100x109\u002FL. ANC ≤ 1.5 x109\u002FL. Hemoglobin ≤ 80 g\u002FL\n19. ECOG≥2\n20. History of stroke or intracranial hemorrhage within 6 months prior to enrollment\n21. Presence of moderate or severe renal function impairment (estimated creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73m2)\n22. Patients with mild, moderate, or severe hepatic impairment or inadequate liver function (total bilirubin \\> 23 umol\u002FL, serum albumin \\\u003C 35 g\u002FL, INR \\> 1.70)\n23. Known hypersensitivity to E-coli derived proteins, isunakinra or any component of the product",{"count":184,"type":21},[614,63],"PHASE1","This study is a phase I\u002FII open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1 inhibitor-pembrolizumab-based neoadjuvant chemotherapy (NAC\u002FP) by changing the tumor microenvironment (TME) via reducing the recruitment of immunosuppressive tumorassociated macrophages (TAMs) and increasing activated cytotoxic T-lymphocytes (CTLs).",[617],"Triple-Negative Breast Cancer (TNBC)","2026-07-06",{"date":576,"type":43},{"date":320,"type":21},{"date":622,"type":21},"2034-08",{"name":49,"class":50},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":61,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":51},"100632112","fecal-microbiota-transplantation-in-patients-undergoing-chimeric-antigen-receptor-t-cell-therapy-and-allogeneic-stem-cell-transplant-a-pilot-study-100632112","NCT07509450","Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study","FMT","Inclusion Criteria:\n\n1. Men and women ≥ 18 years of age\n2. Diagnosis of the following:\n\n   1. Indolent or aggressive B-cell lymphoma eligible for standard or care CAR-T therapy (Cohort A), or\n   2. Patients with AML or high risk MDS with indication to undergo reduced-intensity conditioning alloSCT, with an available matched related, unrelated, or haploidentical donor (Cohort B)\n3. ECOG 0-1\n4. Adequate marrow function defined by:\n\n   1. Hemoglobin \\>80 g\u002FL without transfusion dependence within the last 7 days\n   2. Platelet count \\>20 x 109\u002FL without transfusion dependence within the last 7 days\n   3. Neutrophil count \\>1.0 x 109\u002FL without growth factor support within the last 7 days\n5. Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \\\u003C 1.5 x ULN (unless documented Gilbert's syndrome)\n6. Adequate renal function as defined as creatinine clearance ≥ 30 mL\u002Fmin directly measured with a 24-hour urine collection or calculated according to the modified formula of Cockcroft-Gault equation or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation\n7. Life expectancy \\>6 months\n8. Women of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men require an agreement to remain abstinent (ie, refrain from heterosexual intercourse) or use a condom, and an agreement to refrain from donating sperm. Periodic abstinence and withdrawal are not acceptable methods of contraception. Fertility preservation options should be discussed. Examples of highly effective contraceptive methods include an agreement to remain abstinent (ie, refrain from heterosexual intercourse), bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n9. Willing and able to participate in all required evaluations and procedures in this study.\n10. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. For patients undergoing alloSCT (Cohort B): plan to undergo myeloablative conditioning\n2. Use of investigational agents within the last 4 weeks before enrollment.\n3. Active or uncontrolled infection\n4. Autoimmune disorder currently being treated with disease-modifying therapy or with \\>10mg\u002Fday prednisone\n5. Inflammatory bowel disease\n6. History of intestinal perforation\n7. Gastrointestinal surgical procedure within the past 4 weeks before enrollment\n8. Pregnant or breast-feeding patients\n9. HIV infection with detectable viral load or CD4 count \\\u003C200\n10. Serologic status reflecting active hepatitis B or C infection as follows:\n\n    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA. (Note, patients with undetectable HBV DNA are permitted to enroll if they are on Hepatitis B suppressive therapy)\n    2. Patients with presence of hepatitis C virus (HCV) antibody and HCV RNA detectable\n11. History of infection or known colonization with antibiotic resistant organism in the last two years before enrollment (including ESBL, MRSA, VISA, VRSA, VRE, CPE)\n12. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in the study",{"count":632,"type":21},20,[88],"This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.",[636],"Lymphoma Receiving CAR-T Therapy",{"date":638,"type":43},"2026-07-08",{"date":640,"type":43},"2026-06-02",{"date":642,"type":21},"2029-06-02",{"name":49,"class":50},""]